IMRX logo

IMMUNEERING CORP - CLASS A

IMRXNASDAQ
🏆 #3489 by market capUS Equity
$462.65▲ $32.89 (+7.11%)
Simulated price
🔔
Track IMRX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.1%
7d▲ 10438.7%
14d▲ 10273.3%
30d▲ 9171.5%
ytd▲ 6941.9%
1y▲ 6533.0%
🏦Market Cap
$267M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
28.0%
Moderate
💵FCF Margin
—
⚖️P/S Ratio
534.4x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
$456.80 – $467.24
52-Week Range
$3.86 – $8.48
Volume
$2.81B
Avg Volume
$2.11B
Shares Outstanding
64.7M
Next Earnings
Nov 18, 2026

Fundamentals Snapshot

Annual Revenue
$500,000
Last Q Revenue
$130,420
P/E Ratio
—
P/S Ratio
534.4x
EPS (TTM)
$-1.03
Dividend Yield
—
Dilution (1yr)
+108.0%

Why Investors Own IMRX

  • ✓High-growth profile — revenue up +18.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 37% gross margin and 11% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IMRX logo

IMMUNEERING CORP - CLASS A

IMRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
50.1%▲ +12.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$59M▼ −7.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$45M▼ −17.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
64.6M▲ +108.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$125M▲ +$93M YoY
StockOtter · stockotter.space

About IMMUNEERING CORP - CLASS A

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$581.79
▲ +25.8% Upside
High Target$686.70
Low Target$431.07
Based on 34 analysts

Latest News & Updates

🚀
CNBC·2h ago

IMMUNEERING CORP - CLASS A tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift IMRX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

IMMUNEERING CORP - CLASS A announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.